This predictions were verified in in vitro experiments with A375 melanoma cells subjected to treatment with the two BRAF inhibitors sorafenib and B0R (2,6-difluoro-N-(3-methoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-3-[(propylsulfonyl) amino]benzamide) at different doses, alone or in combination. This evidence concerns the gene BRAF and melanoma.